Telix Pharmaceuticals Ltd. (TLX) saw its stock surge 10% in after-hours trading on Tuesday, following the announcement that a research center in Miami has begun recruiting and dosing patients for the company's Phase 3 clinical trial of TLX591, an investigational treatment for advanced prostate cancer.
The ProstACT Global Phase 3 trial is evaluating TLX591, a radioantibody-drug conjugate (rADC) that targets prostate-specific membrane antigen (PSMA), in combination with standard-of-care therapies for metastatic castration-resistant prostate cancer (mCRPC). The trial aims to assess the safety and efficacy of TLX591 as a first-line or second-line treatment option for this patient population.
The Biogenix Molecular Research Center in Miami has successfully administered the first two doses of TLX591 to a local patient and continues to recruit eligible participants for the trial. According to the center's director, Dr. Frankis Almaguel, there is a significant unmet need for effective combination therapies in mCRPC, and TLX591 has shown promising results in earlier-stage trials.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。